Jamie Yoon
Adult Health · Los Angeles, CANPI 1093486953
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 229 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,709, 7.0 times the $244 reported in 2021. Among adult health clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 229 payments — averaging $23.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$794
- Lilly USA, LLC$618
- AstraZeneca$583
- Novo Nordisk$466
- Aimmune Therapeutics, Inc.$301
- Boehringer Ingelheim$297
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,343100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 40 | $794 |
| Lilly USA, LLC | 29 | $618 |
| AstraZeneca | 26 | $583 |
| Novo Nordisk | 13 | $466 |
| Aimmune Therapeutics, Inc. | 11 | $301 |
| Boehringer Ingelheim | 12 | $297 |
| IBSA Pharma Inc. | 8 | $262 |
| Nestle Healthcare Nutrition Inc. | 11 | $252 |
| Sumitomo Pharma America, Inc. | 10 | $241 |
| Bayer | 11 | $234 |
| Lundbeck LLC | 5 | $133 |
| Novartis | 8 | $132 |
| AbbVie | 5 | $124 |
| Ironwood Pharmaceuticals, Inc | 5 | $118 |
| Eisai Inc. | 3 | $97 |
| Vivus LLC | 4 | $83 |
| Dexcom, Inc. | 4 | $79 |
| Amarin Pharma, Inc. | 3 | $69 |
| GSK | 3 | $64 |
| Scilex Pharmaceuticals Inc. | 3 | $57 |
| Phathom Pharmaceuticals, Inc. | 2 | $55 |
| Gilead | 2 | $52 |
| Esperion Therapeutics, Inc. | 2 | $52 |
| Merck | 1 | $28 |
| Biogen | 1 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Exact Sciences | 1 | $24 |
| Shield Therapeutics Inc | 1 | $23 |
| Pfizer | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Genentech USA, Inc. | 2 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,343 in reported general payments places this provider in the 90th percentile of 785 adult health providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 361 | $431,207 |
| JanuviaSitagliptin Phosphate | 268 | $223,365 |
| VascepaIcosapent Ethyl | 547 | $221,773 |
| JardianceEmpagliflozin | 228 | $186,612 |
| FarxigaDapagliflozin Propanediol | 204 | $145,262 |
| Cyclosporine | 223 | $137,245 |
| EliquisApixaban | 126 | $85,932 |
| TradjentaLinagliptin | 102 | $77,707 |
| JanumetSitagliptin Phos/Metformin Hcl | 106 | $77,336 |
| OzempicSemaglutide | 59 | $69,865 |
| DapagliflozinDapagliflozin Propanediol | 90 | $68,641 |
| ProliaDenosumab | 40 | $68,089 |
| ZenpepLipase/Protease/Amylase | 50 | $57,147 |
| LinzessLinaclotide | 106 | $56,665 |
| RestasisCyclosporine | 62 | $53,694 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Restasis, Namzaric | $124 | $553,103549 claims |
| MerckJanuvia, Janumet, Janumet Xr | $28 | $308,225389 claims |
| Boehringer IngelheimJardiance, Tradjenta | $297 | $264,319330 claims |
| AstraZenecaFarxiga, Brilinta | $583 | $155,899228 claims |
| AmgenProlia, Evenity (2 Syringes) | $794 | $105,29555 claims |
| PfizerEliquis | $23 | $85,932126 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $618 | $76,58074 claims |
| Novo NordiskOzempic | $466 | $69,86559 claims |
| Aimmune Therapeutics, Inc.Zenpep | $301 | $57,14750 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $241 | $39,22968 claims |
| GileadVemlidy | $52 | $17,00012 claims |
| IBSA Pharma Inc.Licart | $262 | $14,02720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 785 adult health providers in California.
Other adult health in Los Angeles
- Karolina FaysmanLos Angeles$1.1M
- Linda BuckLos Angeles$170K
- Lisa HinemanLos Angeles$29K
- Tammy HarperLos Angeles$11K
- Jennifer LettsomeLos Angeles$6K
- Melissa LeeLos Angeles$5K
- Naomi PesynaAnaheim$141K
- Stacy GrissenEncinitas$82K
- Kimberly PodsadaSan Diego$78K
- Brenda PatrickSan Leandro$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.